After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug

After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug zbecker Fri, 09/13/2024 - 11:06